Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer

被引:10
|
作者
Gupta, Swati [1 ]
Mani, Navin R. [1 ]
Carvajal-Hausdorf, Daniel E. [1 ,2 ]
Bossuyt, Veerle [1 ]
Ho, Kenneth [3 ]
Weidler, Jodi [4 ]
Wong, Wendy [3 ]
Rhees, Brian [3 ]
Bates, Michael [4 ]
Rimm, David L. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA
[2] Univ Desarrollo, Fac Med, Clin Alemana, Anat Patol, Santiago, Chile
[3] Cepheid, Div Oncol Res & Dev, Oncol, Sunnyvale, CA USA
[4] Cepheid, Med & Sci Affairs & Strategy, Oncol, Sunnyvale, CA USA
关键词
MESSENGER-RNA; IN-SITU; IMMUNOHISTOCHEMISTRY; CARCINOMA; TAMOXIFEN; ASSAY;
D O I
10.1038/s41374-018-0064-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
An on-demand, closed RT-qPCR, the GeneXpert (GX) system, has the potential to provide biomarker information in low-resourced settings and elsewhere. We used this system with a research use only version of the Breast Cancer STRAT4 cartridge that measures the mRNA expression levels of ERBB2, ESR1, PGR, and MKi67. Here we evaluated the impact of non-macrodissected (non m-d) versus macrodissected (m-d) samples using STRAT4 on formalin-fixed, paraffin-embedded (FFPE) core needle biopsies. Two cohorts were assessed: (1) 60 FFPE infiltrating ductal carcinoma (IDCA) cases and (2) 20 FFPE IDCA cases with ductal carcinoma in situ (DCIS) with a range of HER2 expression as determined by clinical immunohistochemistry and fluorescence in situ hybridization (IHC/FISH). We observed about half of the core needle biopsy area as invasive tumor in both IDCA (mean = 51.5%) and IDCA with DCIS (mean = 53.5%) cohorts, but also found the mRNA levels were independent of tumor area. We found excellent agreement of the mRNA transcript level between the paired samples, m-d versus non m-d, for ERBB2, ESR1, PGR, and MKi67 for both the IDCA and IDCA with DCIS cohorts. No significant difference (P > 0.99) was observed when we compared the mRNA transcript level between the paired samples m-d versus non m-d. In addition, we noted a significant concordance (P < 0.001) between RT-qPCR and IHC/FISH for HER2-positivity, ER-positivity, and PR-positivity, independent of specimen dissection. These data suggest that mRNA expression for ERBB2, ESR, and PGR is sufficiently low in surrounding tissue cells such that macrodissection is not required for assessment of key breast cancer mRNA markers and is independent of the amount of input tumor. This approach may be valuable in settings lacking pathology expertise or using specimen types, such as fine-needle aspirates, where it may be challenging to separate non-tumor from tumor tissue.
引用
收藏
页码:1076 / 1083
页数:8
相关论文
共 50 条
  • [1] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    APMIS, 2020, 128 (11) : 573 - 582
  • [2] Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer
    El Hadi, Hicham
    Abdellaoui-Maane, Imane
    Kottwitz, Denise
    El Amrani, Manal
    Bouchoutrouch, Nadia
    Qmichou, Zineb
    Karkouri, Mehdi
    ElAttar, Hicham
    Errihani, Hassan
    Fernandez, Pedro L.
    Bakri, Youssef
    Sefrioui, Hassan
    Moumen, Abdeladim
    GENE, 2017, 605 : 114 - 122
  • [3] A Comparison of IHC and FISH Cytogenetic Methods in the Evaluation of HER2 Status in Breast Cancer
    Wesola, Marta
    Jelen, Michal
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 24 (05): : 899 - 903
  • [4] Testing HER2 in Breast Cancer A Comparative Study on BRISH, FISH, and IHC
    Bruegmann, Anja
    Lelkaitis, Giedrius
    Nielsen, Soren
    Jensen, Kirsten Gadgaard
    Jensen, Vibeke
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2011, 19 (03) : 203 - 211
  • [5] Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer
    Roepman, Paul
    Horlings, Hugo M.
    Krijgsman, Oscar
    Kok, Marleen
    Bueno-de-Mesquita, Jolien M.
    Bender, Richard
    Linn, Sabine C.
    Glas, Annuska M.
    van de Vijver, Marc J.
    CLINICAL CANCER RESEARCH, 2009, 15 (22) : 7003 - 7011
  • [6] Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer
    Chen, Lili
    Chen, Yanyang
    Xie, Zhongpeng
    Luo, Jiao
    Wang, Yuefeng
    Zhou, Jianwen
    Huang, Leilei
    Li, Hongxia
    Wang, Linhai
    Liu, Pei
    Shu, Man
    Zhang, Wenhui
    Ke, Zunfu
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 194 (03) : 517 - 529
  • [7] Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance
    Emde, Anna
    Mahlknecht, Georg
    Maslak, Kerstin
    Ribba, Benjamin
    Sela, Michael
    Possinger, Kurt
    Yarden, Yosef
    TRANSLATIONAL ONCOLOGY, 2011, 4 (05): : 293 - 300
  • [8] A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer
    Fatemeh Bahreini
    Ali Reza Soltanian
    Parvin Mehdipour
    Breast Cancer, 2015, 22 : 615 - 625
  • [9] A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer
    Bahreini, Fatemeh
    Soltanian, Ali Reza
    Mehdipour, Parvin
    BREAST CANCER, 2015, 22 (06) : 615 - 625
  • [10] HER2 testing in metastatic breast cancer-Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?
    Liwski, Christopher R.
    Castonguay, Mathieu C.
    Barnes, Penny J.
    Rayson, Daniel
    Bethune, Gillian C.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2022, 59